Meeting News CoverageVideo

VIDEO: MA.17R trial shows ‘clear benefit’ of extended hormonal therapy

CHICAGO — Ron Bose, MD, PhD, medical oncologist at Washington University School of Medicine in St. Louis, reviews the positive results from the MA.17R trial at the ASCO Annual Meeting.

In the trial, researchers randomly assigned patients with hormone receptor–positive breast cancer to receive an additional 5 years of letrozole or placebo after the standard 5 years of therapy. Results showed extended treatment reduced the risk for recurrence by a 34% (HR = 0.66; P = .01).

“At a practical level, this trial demonstrates that there is clear benefit of extended use of an aromatase inhibitor in hormone receptor–positive breast cancer patients in whom osteoporosis or fracture risk can be controlled,” Bose said.

CHICAGO — Ron Bose, MD, PhD, medical oncologist at Washington University School of Medicine in St. Louis, reviews the positive results from the MA.17R trial at the ASCO Annual Meeting.

In the trial, researchers randomly assigned patients with hormone receptor–positive breast cancer to receive an additional 5 years of letrozole or placebo after the standard 5 years of therapy. Results showed extended treatment reduced the risk for recurrence by a 34% (HR = 0.66; P = .01).

“At a practical level, this trial demonstrates that there is clear benefit of extended use of an aromatase inhibitor in hormone receptor–positive breast cancer patients in whom osteoporosis or fracture risk can be controlled,” Bose said.

    See more from ASCO Annual Meeting